Companies across the biopharmaceutical industry have been busy investing in a variety of strategies to improve clinical trial diversity, ranging from partnerships with diverse community organizations to greater adoption of decentralized trials. But a macro-level assessment reveals varying degrees of progress, with some players making enormous strides and others that still have a lot of work ahead of them.
A November report from the Pharmaceutical Research and Manufacturers of America (PhRMA) and Deloitte, based on interviews with 31 member companies and hundreds of other stakeholders, gives a broad view
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?